These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38070662)

  • 21. Belimumab--an anti-BLyS human monoclonal antibody for rheumatoid arthritis.
    Jin X; Ding C
    Expert Opin Biol Ther; 2013 Feb; 13(2):315-22. PubMed ID: 23268610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial.
    Banham GD; Flint SM; Torpey N; Lyons PA; Shanahan DN; Gibson A; Watson CJE; O'Sullivan AM; Chadwick JA; Foster KE; Jones RB; Devey LR; Richards A; Erwig LP; Savage CO; Smith KGC; Henderson RB; Clatworthy MR
    Lancet; 2018 Jun; 391(10140):2619-2630. PubMed ID: 29910042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
    Wilkinson C; Henderson RB; Jones-Leone AR; Flint SM; Lennon M; Levy RA; Ji B; Bass DL; Roth D
    Arthritis Res Ther; 2020 May; 22(1):102. PubMed ID: 32366280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-huCD20 antibody therapy for antibody-mediated rejection of renal allografts in a mouse model.
    Abe T; Ishii D; Gorbacheva V; Kohei N; Tsuda H; Tanaka T; Dvorina N; Nonomura N; Takahara S; Valujskikh A; Baldwin WM; Fairchild RL
    Am J Transplant; 2015 May; 15(5):1192-204. PubMed ID: 25731734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.
    Riccobene TA; Miceli RC; Lincoln C; Knight Y; Meadows J; Stabin MG; Sung C
    J Nucl Med; 2003 Mar; 44(3):422-33. PubMed ID: 12621010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preventative effect of TSPO ligands on mixed antibody-mediated rejection through a Mitochondria-mediated metabolic disorder.
    Zhang Y; He J; Yang Z; Zheng H; Deng H; Luo Z; Sun Q; Sun Q
    J Transl Med; 2023 May; 21(1):295. PubMed ID: 37131248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of BLyS/BLyS receptors in anti-chromatin B cell regulation.
    Hondowicz BD; Alexander ST; Quinn WJ; Pagán AJ; Metzgar MH; Cancro MP; Erikson J
    Int Immunol; 2007 Apr; 19(4):465-75. PubMed ID: 17369193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease.
    Lietz K; John R; Burke E; Schuster M; Rogers TB; Suciu-Foca N; Mancini D; Itescu S
    Circulation; 2005 Oct; 112(16):2468-76. PubMed ID: 16230499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
    Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
    Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia.
    Bishton M; Spencer A; Dickinson M; Ritchie D
    Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):575-8. PubMed ID: 23773449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
    Furie R; Stohl W; Ginzler EM; Becker M; Mishra N; Chatham W; Merrill JT; Weinstein A; McCune WJ; Zhong J; Cai W; Freimuth W;
    Arthritis Res Ther; 2008; 10(5):R109. PubMed ID: 18786258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In the absence of natural killer cell activation donor-specific antibody mediates chronic, but not acute, kidney allograft rejection.
    Yagisawa T; Tanaka T; Miyairi S; Tanabe K; Dvorina N; Yokoyama WM; Valujskikh A; Baldwin WM; Fairchild RL
    Kidney Int; 2019 Feb; 95(2):350-362. PubMed ID: 30503624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation and characterization of human B lymphocyte stimulator blocking monoclonal antibody.
    Zhuang W; Zhang J; Pei L; Fang S; Liu H; Wang R; Su Y
    Mol Immunol; 2016 Sep; 77():141-7. PubMed ID: 27505709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B-Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein, in Healthy Chinese Subjects.
    Xie J; Fan X; Su Y; Zhou H; Cao S; Zhu X; Zhu M; He C; Wang Y; Fan L; Ge Q; Zhu J; Liu B; Chen X; Xie Y; Ma L; Liu Y; Chen J; Wang H; Li Z
    Clin Pharmacol Drug Dev; 2022 Nov; 11(11):1273-1283. PubMed ID: 35844038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of Donor-Specific Antibody Production After Organ Transplantation by Valproic Acid: A Histone Deacetylase Inhibitor.
    Ye J; Li J; Zhou M; Xia R; Liu R; Yu L
    Transplantation; 2016 Nov; 100(11):2342-2351. PubMed ID: 27140514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Artemisinin Attenuates Transplant Rejection by Inhibiting Multiple Lymphocytes and Prolongs Cardiac Allograft Survival.
    Yang Z; Han F; Liao T; Zheng H; Luo Z; Ma M; He J; Li L; Ye Y; Zhang R; Huang Z; Zhang Y; Sun Q
    Front Immunol; 2021; 12():634368. PubMed ID: 33717174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns of de novo allo B cells and antibody formation in chronic cardiac allograft rejection after alemtuzumab treatment.
    Kwun J; Oh BC; Gibby AC; Ruhil R; Lu VT; Kim DW; Page EK; Bulut OP; Song MQ; Farris AB; Kirk AD; Knechtle SJ; Iwakoshi NN
    Am J Transplant; 2012 Oct; 12(10):2641-51. PubMed ID: 22759336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab.
    Regola F; Piantoni S; Lowin T; Archetti S; Reggia R; Kumar R; Franceschini F; Airò P; Tincani A; Andreoli L; Pongratz G
    Front Pharmacol; 2019; 10():433. PubMed ID: 31105569
    [No Abstract]   [Full Text] [Related]  

  • 39. In vitro immunoglobulin production in long-term renal transplant recipients.
    Landsberg DN; Bush LE; Cardella CJ
    Transplantation; 1985 Apr; 39(4):389-92. PubMed ID: 3885489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
    Espinosa G; Cervera R
    Drugs Today (Barc); 2010 Dec; 46(12):891-9. PubMed ID: 21589946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.